DEGS1 and type 2 diabetes mellitus: Finally, our findings suggest that 4-HPA might be considered solely a Degs1 inhibitor, because it fails to promote ceramide formation and this compound could, therefore, be exploited in diseases, such as T2D, where the major therapeutic objective is to abrogate ceramide-induced metabolic deregulation and to avoid cytotoxicity.